These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 25670221)

  • 21. PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
    Pongas G; Cheson BD
    Semin Oncol; 2016 Dec; 43(6):647-654. PubMed ID: 28061982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Idelalisib: targeting PI3Kδ in B-cell malignancies.
    Gilbert JA
    Lancet Oncol; 2014 Mar; 15(3):e108. PubMed ID: 24809089
    [No Abstract]   [Full Text] [Related]  

  • 23. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
    Sanford DS; Wierda WG; Burger JA; Keating MJ; O'Brien SM
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):385-91. PubMed ID: 25817936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
    Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
    Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
    Krause G; Hassenrück F; Hallek M
    Drug Des Devel Ther; 2018; 12():2577-2590. PubMed ID: 30174412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
    Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
    Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idelalisib for treatment of B-cell malignancies.
    Do B; Mace M; Rexwinkle A
    Am J Health Syst Pharm; 2016 Apr; 73(8):547-55. PubMed ID: 26933132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
    Palazzo A; Herter S; Grosmaire L; Jones R; Frey CR; Limani F; Bacac M; Umana P; Oldham RJ; Marshall MJE; Cox KL; Turaj AH; Cragg MS; Klein C; Carter MJ; Tannheimer S
    J Immunol; 2018 Apr; 200(7):2304-2312. PubMed ID: 29453281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idelalisib for the treatment of indolent non-Hodgkin's lymphoma.
    Lopez JP; Jimeno A
    Drugs Today (Barc); 2014 Feb; 50(2):113-20. PubMed ID: 24619588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.
    Cuneo A; Barosi G; Danesi R; Fagiuoli S; Ghia P; Marzano A; Montillo M; Poletti V; Viale P; Zinzani PL
    Hematol Oncol; 2019 Feb; 37(1):3-14. PubMed ID: 30187496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Idelalisib for chronic lymphocytic leukemia.
    Brown JR
    Clin Adv Hematol Oncol; 2014 Dec; 12(12):846-8. PubMed ID: 25674842
    [No Abstract]   [Full Text] [Related]  

  • 33. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
    Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
    Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
    Wang X; Ding J; Meng LH
    Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma.
    Okoli TC; Peer CJ; Dunleavy K; Figg WD
    Cancer Biol Ther; 2015; 16(2):204-6. PubMed ID: 25756507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
    Molica S
    Expert Rev Hematol; 2015 Jun; 8(3):277-81. PubMed ID: 25804936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
    Isidori A; Loscocco F; Visani G; Paolasini S; Scalzulli P; Musto P; Perrone T; Guarini A; Pastore D; Mazza P; Tonialini L; Pavone V; De Santis G; Tarantini G
    Br J Haematol; 2022 Nov; 199(3):339-343. PubMed ID: 36002151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idelalisib-associated Colitis: Histologic Findings in 14 Patients.
    Weidner AS; Panarelli NC; Geyer JT; Bhavsar EB; Furman RR; Leonard JP; Jessurun J; Yantiss RK
    Am J Surg Pathol; 2015 Dec; 39(12):1661-7. PubMed ID: 26448188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PI3Kδ inhibition hits a sensitive spot in B cell malignancies.
    Vanhaesebroeck B; Khwaja A
    Cancer Cell; 2014 Mar; 25(3):269-71. PubMed ID: 24651009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
    Burger JA; Okkenhaug K
    Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.